SOS2

Across TCGA pan-cancer cohorts, SOS2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SOS2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SOS2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SOS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, LUAD, and PRAD are the cancer types where SOS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.146	0.705	.010	12	view →
LUAD	OS	Median	All	0.232	0.675	.003	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
COAD	OS	Median	III,IV	0.183	0.696	.049	3	view →
UCEC	DFS	Median	II,III,IV	0.868	0.435	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SOS2–CESC (DFS)

Open the CESC breakdown →